AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05948943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 2-5 years of age will receive dose 3 of alpelisib
Study NCT05948943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Stage 2, participants will receive matching placebo for 24 weeks of the study
Study NCT05813093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Accelerated iTBS treatment
Study NCT05238116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile aqueous liquid for Nebulization
Study NCT06088303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjunctive writing to amplify response and engagement (AWARE)
Description: AWARE includes two components: 1) patients complete brief writing prompts asking about their experiences in treatment, and 2) therapists review patients' responses and facilitate guided discussion related to patients' experiences during check-ins at the beginning of each session.
Study NCT06088303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive processing therapy (CPT)
Description: CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.
Study NCT06088303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT)
Description: CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.
Study NCT06088303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
Study NCT06088303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE)
Description: PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
Study NCT06458387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active protein supplementation
Description: The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day. NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active protein supplementation arm were protein supplementation at over 1.5 g/kg/day during first 3 days after ICU admission. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.
Study NCT06458387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional protein supplementation
Description: The participants in conventional protein supplementation arm received conservative nutritional management without specific protein targets.
Study NCT06529250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAD
Description: Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.
Study NCT06529250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin+Cytarabine
Description: Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.
Study NCT06550050 — intervention group
Intervention type: BEHAVIORAL
Intervention: Radiation
Description: Standard of care
Study NCT05687760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bromelain
Description: is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
Study NCT05687760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: calcium hydroxide
Study NCT05533242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 labeled 6A10-Fab-fragments
Description: The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
Study NCT04344860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Von Willebrand factor
Description: Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
Study NCT05561179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Description: Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms.
Study NCT05561179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride injection (control group)
Description: Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms.
Study NCT04817527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol
Description: Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
Study NCT06181279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized PEEP group
Description: Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
Study NCT06181279 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixed PEEP group
Description: After the same RM, PEEP is fixed at 8 cmH2O.
Study NCT04344860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injection [Cyklokapron]
Description: Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
Study NCT04994483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
Study NCT04994483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given b.i.d. for 52 weeks.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks.
Study NCT05012787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
Description: Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
Study NCT05012787 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Havrix
Description: Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
Study NCT05012787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; 0.9% saline
Description: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil Placebo
Description: The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Solriamfetol
Description: The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Solriamfetol Placebo
Description: The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Study NCT06404086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Study NCT06404086 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tailored lighting (TL) Active
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study NCT06404086 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study NCT04717908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 400 mg once daily for 2 weeks then 200mg 3 times per week;
Study NCT04717908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 1500 mg daily
Study NCT04717908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg daily
Study NCT04888767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training Hight Intensity Program
Description: * Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible
Study NCT04869995 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: An individual semi-structured interview per surgeon, according to an interview guide.
Study NCT05754528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care administration of Endocrine therapy
Description: Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
Study NCT05754528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-frequency escalation administration of Endocrine therapy
Description: Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
Study NCT05066061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: usual process
Study NCT05066061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiolytic and analgesic gas
Description: add relaxing gas
Study NCT05066061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality mask
Description: use Virtual reality mask Oculus Quest with age-appropriate software
Study NCT05646485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis
Description: Urine analysis (every 6 months for 2 years); Patients with \<3 red blood cells (RBCs) per high-powered field (HPF) will repeat screening at 6-month intervals for an average of 2 years.~If RBCs are 3-25 RBSc/HPF- subjects will undergo- \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\].~If >25 RBCs, subjects will get - \[cystoscopy + Upper tract imaging\].
Study NCT04807595 — intervention group
Intervention type: OTHER
Intervention: None (Observational study)
Description: The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
Study NCT05453487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coadministration
Description: the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
Study NCT05453487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
Study NCT05453487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: received three dose of rabies vaccine
Study NCT06113549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee Joint Distraction (KD)
Description: Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
Study NCT05954312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVD-130037
Description: Oral tablets
Study NCT06340529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
Study NCT04717908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: ≤50kg 500 mg daily, >50kg 750mg daily;
Study NCT04717908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 100 mg daily;
Study NCT06340529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
Study NCT04581590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
Study NCT04581590 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
Study NCT06113549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee Prosthesis
Description: A total or unicompartmental knee prosthesis
Study NCT06389227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic ecological approach (DEA)
Description: The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
Study NCT06389227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional training group
Description: The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
Study NCT03814850 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard Manual Aneroid Sphygmomanometer
Description: Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
Study NCT03814850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Manual Aneroid Sphygmomanometer
Description: Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
Study NCT05472415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognicise
Description: a combination of cognition and exercise training
Study NCT05472415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognicise
Description: a combination of cognition and exercise training